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Abstract  27 
 28 
Tuberculosis (TB) caused by Mycobacterium tuberculosis remains a leading killer worldwide, 29 
and disease control is hampered by ineffective control of persistent infections. Substitution of 30 
moxifloxacin for isoniazid or ethambutol in standard TB regimens reduces treatment duration 31 
and relapse rates in animal studies and four-month regimens were not non-inferior in clinical 32 
trials. Resuscitation promoting factor (RPF) dependent bacilli have recently been implicated in 33 
M. tuberculosis persistence. We aimed to investigate the therapeutic effects of moxifloxacin 34 
substitution in the standard drug regimen for eradicating colony forming count (CFU) positive 35 
and RPF-dependent persistent M. tuberculosis using the Cornell murine model. M. tuberculosis 36 
infected mice were treated with regimens in which either isoniazid or ethambutol were 37 
replaced by moxifloxacin to the standard regimen.  The efficacy of the regimens was compared 38 
to the standard regimen for bacterial CFU count elimination and removal of persistent tubercle 39 
bacilli evaluated using culture filtrate (CF) derived from M. tuberculosis strain H37Rv. We 40 
also measured disease relapse rates. Moxifloxacin-isoniazid substituted regimen achieved total 41 
organ CFU count clearance at 11 weeks post-treatment, faster than standard regimen (14 42 
weeks), and with a 34% lower relapse rate. Moxifloxacin-ethambutol substituted regimen was 43 
similar to standard regimens in these regards. Importantly, neither moxifloxacin-substituted 44 
regimens nor the standard regimen could remove CF-dependent persistent bacilli.  Evaluation 45 
of CF-dependent persistent M. tuberculosis requires confirmation in human studies, and has 46 
implications in future drug design, testing and clinical applications.  47 
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TB caused by Mycobacterium tuberculosis remains a leading cause of mortality worldwide (1). 55 
Current combination antimicrobial regimens require a prolonged 6-month treatment period. 56 
This long regimen leads to poor patient compliance which gives rise to the emergence of drug 57 
resistance and high relapse rates (2). Substitution of moxifloxacin (an 8-methoxy 58 
fluoroquinolone) for drugs in the contemporary anti-TB regimen has shown promise for 59 
improving treatment efficacy (3, 4).  In vivo, replacement of isoniazid with moxifloxacin led to 60 
shortened treatment duration (5, 6), reduced relapse rates (6, 7) and favourable outcomes in 61 
BALB/c and granuloma-forming C3HeB/FeJ mice (8).  In the recent REMox-TB trial, shorter 62 
(four-month) moxifloxacin-replacement regimens (either for isoniazid or ethambutol) in human 63 
clinical trials failed to achieve non-inferiority compared to standard regimens (3, 4),  mainly 64 
due to higher relapse rates (3, 4, 9).  Persistent bacteria that are tolerant to drug therapy may be 65 
implicated in the higher disease relapse (9). 66 
M. tuberculosis persistence is the single most important hurdle hampering effective TB disease 67 
control (10). M. tuberculosis has the ability to survive in a dormant, non-multiplying and 68 
persistent state (11-14).  These persistent bacteria do not grow on solid or liquid media and are 69 
undetectable using the conventional diagnostic methods, however can be resuscitated using 70 
resuscitation promoting factors (RPF) which are present in M. tuberculosis culture supernatant 71 
(15).   Recently, we found that using culture filtrate (CF) containing RPF (15), could induce 72 
persistent bacteria to recommence multiplication, rendering them detectable once more in mice 73 
(16-18). Moreover, these CF-resuscitated tubercle bacilli could be completely eliminated using  74 
high-dose rifampicin regimens, shortening treatment duration with no disease relapses (16, 18).  75 
In this study, we used the Cornell mouse model (19, 20) to investigate the therapeutic impact 76 
of moxifloxacin replacement in standard TB regimen against both CFU count positive and CF-77 
dependent bacteria. We compared the regimens in which either isoniazid or ethambutol were 78 
replaced by moxifloxacin to the standard regimen by measurements of the elimination  rates of 79 
CFU counts, the presence of CF-dependent M. tuberculosis in mouse organs and disease 80 
relapse rates.  81 
  82 
MATERIALS AND METHODS 83 
Bacterium and growth conditions. M. tuberculosis strain H37Rv was mouse-passaged and 84 
grown in 7H9 medium containing 0.05% Tween 80 and supplemented with 10% albumin 85 
dextrose complex (ADC; Becton and Dickinson, UK) at 37°C without disturbance for 15 86 
days. The culture was stored at -70°C for subsequent animal infection. To determine the viable 87 
counts prior to infection, colony forming unit (CFU) counts were performed prior to freezing 88 
and once again after thawing. The CFU counting was carried out by plating serial 10-fold 89 
dilutions of the cultures on 7H11 agar medium supplemented with oleic albumin dextrose 90 
complex (OADC, Becton and Dickinson, UK). Colonies were counted after incubation of 91 
the plates at 37°C for 3 to 4 weeks. Viability was expressed as Log CFU/ml.  The cultures were 92 
subsequently diluted in PBS and used for inoculations in mice.   93 
Cornell mouse model. Moxifloxacin (M) substitution for either isoniazid (H) or ethambutol 94 
(E) in the standard TB drug regimen with rifampicin (R) and pyrazinamide  (Z) was tested 95 
using the Cornell mouse model (19, 20). The model was conducted using the experimental 96 
design and procedure described previously (17).  97 
Female BALB/c mice (6 to 8 weeks old, Harlan UK Ltd) were infected intravenously via the 98 
tail vein with 1.2 × 10
5 
CFU of mouse-passaged M. tuberculosis strain H37Rv per mouse as 99 
described previously (16, 17, 20). The animal husbandry guidelines and all animal experiments 100 
were performed according to the Animals Scientific Procedures Act, 1986 (an Act of the 101 
Parliament of the United Kingdom 1986 c. 14) (Home Office Project licence Number 70/7077) 102 
with approval from St George’s, University of London ethics committee.  103 
As shown in Table 1, control group consisted of 8 infected and untreated mice. The treatment 104 
groups each contained 54 mice which were treated orally (0.2 ml) with RHZE, RHZM and 105 
RMZE regimens, respectively, 5 days per week for 14 weeks. The dosages for the drugs were 106 
R 10 mg/kg, H 25 mg/kg, Z 150 mg/kg, E 100 mg/kg and M 100 mg/kg.  Rifampicin was 107 
administered 1 hour before the other drugs to avoid drug to drug interactions.   108 
For assessment of treatment efficacy, a sample of 4 mice was sacrificed at 2, 4, and 6 weeks 109 
and 8 mice were sacrificed at 8, 11 and 14 weeks of treatment (Table 1). Mouse lungs and 110 
spleens were transferred into 2 ml tubes each containing 1 ml sterile distilled water and 2 mm 111 
diameter glass beads, followed by homogenizing using a reciprocal shaker (Thermo Hybaid 112 
Ltd) for 40 seconds at 6.5 speed. The CFU counts from each lung and spleen were performed 113 
using serial dilutions of the homogenates to plate on 7H11 agar plates.  114 
At 11 and 14 weeks of treatment, the entire organ homogenates from the 8 mice were aliquoted 115 
equally into three tubes which were used 1. The CFU counting by plating out the organ 116 
homogenate suspension on 6 selective 7H11 agar plates.  2. culturing in 5 ml of selective 117 
Kirchner liquid medium  (21) by the addition of polymyxin B 200 U/ml, carbenicillin 100 118 
mg/l, trimethoprim 20 mg/l and amphotericin B 10 mg/l  (Selectatab, Mast Diagnostica GmbH) 119 
for 4 weeks with subsequent sub-culturing of the entire culture onto Löwenstein-Jensen slopes 120 
for a further 4 weeks and 3. resuscitation of persistent bacteria by culture filtrate. Kirchner 121 
liquid medium was used to isolate different species of mycobacteria from human specimens.  122 
Mitchison et al (21) showed that liquid Kirchner medium, made selective by the addition of the 123 
antimicrobials, was more effective in the isolation of mycobacteria than other media tested. 124 
Culture negative organs were defined as no colonies grown on 7H11 agar plates and no growth 125 
in selective Kirchner liquid medium following inoculation on Löwenstein-Jensen slopes.  126 
Immediately after termination of 14 weeks of chemotherapy, the remaining mice were 127 
administered 0.5 mg/mouse of hydrocortisone acetate by daily oral administration for 8 weeks 128 
to suppress host immunity, followed by CFU counting from lungs and spleens to determine 129 
disease relapse. 130 
Resuscitation of M. tuberculosis in mouse lungs and spleens. For resuscitation of M. 131 
tuberculosis grown in mouse organs, culture filtrates containing RPFs were used as described 132 
previously (15-17). 133 
M. tuberculosis H37Rv was grown in 7H9 medium without disturbance at 37°C for 15 to 20 134 
days until an optical density of 1 to 1.5 was reached. The culture supernatants were collected 135 
by centrifugation at 3000 g for 15 minutes and sterilized by double filtration with 0.2 µm filters 136 
(Sartorius). The sterilized culture filtrates were made selective by the addition of polymyxin B 137 
200 U/ml, carbenicillin 100 mg/l, trimethoprim 20 mg/l and amphotericin B 10 mg/l  138 
(Selectatab, Mast Diagnostica GmbH) and immediately used for broth dilution to count the 139 
most probable number (MPN) of the bacilli (22). 140 
Broth counting of lungs and spleens was performed as serial 10-fold dilutions in which 0.5 ml 141 
of tissue homogenates were added to 4.5 ml of the culture filtrates. At 10-day intervals over a 142 
2-month period of incubation at 37°C, the broth cultures were examined for visible turbidity 143 
changes. Growth of M. tuberculosis in turbid tubes was confirmed by colonial morphology on 144 
7H11 agar plates. The MPN of viable bacilli was then estimated from the patterns of positive 145 
and negative tubes accosting to the method of US Food and Drug Administration (22). The 146 
absence of microorganisms other than mycobacteria from turbid tubes was confirmed by 147 
plating on blood agar medium (Oxoid) and Sabouraud dextrose agar (Oxoid). In order to assess 148 
the sterility of culture filtrates free of M. tuberculosis, tubes containing culture filtrates were 149 
incubated at 37°C for 2 months to ensure  the absence of M. tuberculosis in the culture filtrates.  150 
Statistical analysis.  A simple model for mono-exponential bacterial growth and elimination 151 
(17, 23)  was fitted to the profiles of CFU vs. time obtained experimentally. As simultaneously 152 
occurring exponential replication and death rates cannot be differentiated with this type of data, 153 
a “knet” exponential rate constant was estimated separately before treatment began 154 
(“knet_no_drug” where it would take a net positive value) and during treatment 155 
(“knet_with_drug” where it would take a net negative value). During therapy, knet is a 1st order 156 
elimination rate constant which can be interpreted as the slope of the modelled line fit through 157 
the logarithmic-transform of the data (with units in these data of wk
-1
).  Parameter estimation 158 
was carried out with nonlinear regression using the nonlinear least squares optimisation 159 
function “lsqnonlin” as part of the “pracma” package in the R statistical software language, 160 
with an objective function weighted by 1/(predicted value)^2. Standard errors of parameter 161 
estimates were calculated using the method descripted previously (24)  with the Jacobian of 162 
model parameter sensitivities estimated using a numerical central difference method. The 163 
datasets comprised from multiple individual subject animals were treated as a naïve pool for 164 
data analysis purposes  (25) rather than using the average of the data at each time-point. The 165 
significance of differences between model parameter estimates under different therapies was 166 
examined with pairwise Z-tests incorporating a Bonferroni correction of 3, where P values 167 
˂0.017 would be considered significant. The significance of differences between the relapse 168 
rates was determined with pairwise Fisher’s exact tests also with a Bonferroni correction of 3, 169 
with P values ˂0.017 considered significant. 170 
  171 
RESULTS 172 
Treatment with moxifloxacin containing regimens in the Cornell mouse model. In the 173 
Cornell model, after three weeks of infection, mean CFU counts in the organs reached log 7.54 174 
in lungs and 6.99 in spleens (Table 2).  175 
When we investigated the substitution of moxifloxacin for either isoniazid or ethambutol in the 176 
current drug regimen on the rate of bacterial CFU elimination, we found that the early 177 
bactericidal activities were similar amongst the three drug regimens, which were 99% kill at 178 
2.2 weeks for moxifloxacin replacing isoniazid regimen (RMZE), 2.7 weeks for standard 179 
regimen (RHZE) and 3 weeks for moxifloxacin replacing ethambutol regimen (RHZM). 180 
Treatment with RMZE increased the rate of bacterial elimination showing undetectable CFU 181 
counts at 11 weeks compared to 14 weeks for the standard regimen and moxifloxacin replacing 182 
ethambutol regimen (Table 2).  183 
These observations coincided with bactericidal activities as assessed using the mono-184 
exponential bacterial elimination rate constants (Fig 1, and Table 3) where the exponential rate 185 
constants (logarithmic base 10) for net bacterial elimination during treatment (knet_with_drug) for 186 
standard, moxifloxacin replacing ethambutol and moxifloxacin replacing isoniazid regimens 187 
were -0.46, -0.50 and -0.65, in lungs and -0.46, -0.46 and -0.60 in spleens, respectively (Table 188 
3). The higher the absolute value of this elimination rate constant (i.e. the steeper the slope of 189 
the elimination on the logarithmic scale with units of wk
-1
), the quicker the exponential 190 
elimination rate of CFU counts in the organs These values indicate therefore that compared to 191 
the standard therapy, substitution of moxifloxacin for isoniazid gives a significant increase in 192 
bacterial elimination in both lungs and spleens while substitution of moxifloxacin for 193 
ethambutol makes a statistically indistinguishable difference.  194 
In the CFU count free organs, no tubercle bacilli were recovered which was determined by 195 
negative cultures of the organ homogenates in selective Kirchner broth for 4 weeks followed 196 
by growth on Löwenstein–Jensen medium. 197 
Post-treatment level of CF-resuscitated MPN in the Cornell model. In order to investigate 198 
the effect of moxifloxacin containing regimens on the post-treatment level of persistent bacilli 199 
through CF-induced resuscitation, lung and spleen homogenates at the weeks of treatment 200 
when CFU counts reached zero for each of the regimens were incubated with culture filtrates. 201 
As shown in Table 4, after 14 weeks of treatment with RHZE and RHZM, high levels of CF-202 
resuscitated bacilli remained in both lungs and spleens. For RMZE treatment, at 11 weeks post-203 
treatment, although CFU counts were zero, there were average 2.96 and 3.01 log of CF-204 
resuscitated MPN of bacilli per lung and spleen, respectively. At 14 weeks of treatment, there 205 
were still 2-log MPN of the bacilli present (Table 4).  The numbers of CF-dependent bacteria at 206 
14 weeks amongst the three treatment groups were not significantly different (p ˃0.05, n = 8).  207 
Relapse rate of treatment with the moxifloxacin containing regimens in the Cornell 208 
model. After 8 weeks of high dosage steroid immunosuppression, disease relapse rates for the 209 
treatment with the three drug regimens were determined by the percentage of mice that 210 
developed positive M. tuberculosis cultures (CFU counts) in lungs, spleens or both. As shown 211 
in Table 5,  treatment with the standard regimen RHZE gave rise to positive organs in 19 out of 212 
21 mice (90% relapse rate) and RHZM led to 95% relapse rate after 14 weeks of treatment. In 213 
contrast, treatment with RMZE resulted in 59% of relapse (P = 0.03 vs. RHZE, P = 0.009 vs. 214 
RHZM, P < 0.017 significant at 0.05 level after Bonferroni correction for 3 pairwise 215 
comparisons). 216 
We also measured CF-dependent bacilli using culture filtrates in the organs which 217 
showed CFU count negative after 8 weeks of steroid treatment. As shown in Table 5, 218 
the negative organs in each treatment group contained high numbers of CF-dependent 219 
cells. There are average 3.3, 3.51 and 3.05 logs of MPN per organ in the groups of 220 
RHZE, RHZM and RMZE, respectively.   221 
  222 
DISCUSSION 223 
This is the first study, using the reliable Cornell mouse model, to characterize the therapeutic 224 
efficacy of moxifloxacin-replacement in vivo against CF-dependent M. tuberculosis persistent 225 
cells. Compared to standard TB regimen, we found that moxifloxacin replacement for 226 
isoniazid: (i) failed to remove CF-dependent bacilli, despite having (ii) faster organ CFU count 227 
elimination rates and (iii) lower disease relapse rates. In contrast, moxifloxacin replacement for 228 
ethambutol failed to demonstrate any therapeutic benefits compared to the standard regimen. 229 
These results of CF resuscitation need to be confirmed in human studies, but may provide a 230 
novel mechanistic explanation for the results of moxifloxacin-replacement regimens in clinical 231 
trials. Findings in this study also have important future implications in TB novel drug design, 232 
diagnostic testing and clinical applications.  233 
Moxifloxacin-replaced drug regimens are ineffective against CF-dependent tubercle 234 
bacilli. The greater therapeutic efficacy and lower relapse rates achieved with moxifloxacin-235 
isoniazid replacement regimen, as compared to the standard regimen, in this study is consistent 236 
with previous reports (5-8). De Groote et al demonstrated that moxifloxacin replacing isoniazid 237 
in the standard regimen gave rise to 63% disease relapse (6). In other studies, Nuermberger and 238 
colleagues showed that the same drug regimen produced a lower disease relapse at 33.3% (7). 239 
Late studies using two pathologically distinct murine tuberculosis models demonstrated very 240 
similar low disease relapses (8). Our study confirmed this interesting observation showing 56% 241 
relapse, indicating the consistency of the drug regimen in different mouse models.   242 
The underlining mechanisms that moxifloxacin replacing isoniazid was more efficacious than 243 
the standard or moxifloxacin replacing ethambutol regimens were unknown. It has been shown 244 
previously that when mice were treated with rifampicin-isoniazid-pyrazinamide, rifampicin-245 
isoniazid or rifampicin-pyrazinamide for 6 months, rifampicin-pyrazinamide treated group 246 
demonstrated significantly lower relapse rates than the other two groups containing isoniazid 247 
(26), suggesting that isoniazid antagonized the actions of rifampicin-pyrazinamide (26). It is 248 
possible that replacement of isoniazid with moxifloxacin eliminated the antagonistic drug 249 
interaction leading to the rapid organ CFU count clearance in mice.  250 
The use of CFU counts as an end point reflects the clinical observations in patients to a large 251 
degree, which is related to clinical endpoints such as sputum culture conversion in patients (3, 252 
27, 28).  The improved efficacy with moxifloxacin replacement for isoniazid compared to the 253 
standard regimen reflected the clinical outcome in patients to some extent, for example, the 254 
moxifloxacin-isoniazid substitution regimen showed an effective bactericidal activity which 255 
was able to kill CFU count positive bacilli faster than the standard regimen, leading to the 256 
higher sputum culture conversion rate in humans (3, 27, 28).  257 
Despite the improved performance, moxifloxacin-isoniazid replaced regimen was ineffective 258 
against CF-dependent bacterial cells, which has not been demonstrated previously. At 11 259 
weeks and the end of the antibiotic therapy, despite the elimination of CFU count positive 260 
bacilli, considerable MPN of CF-dependent bacilli remained in all the mice, which were 261 
similar to those treated with the standard drug regimen or the moxifloxacin-ethambutol 262 
replaced regimen. This indicated that although the moxifloxacin-isoniazid replaced regimen 263 
was more bactericidal than the standard regimen, the drug regimen failed to show improved 264 
sterilizing activity against persistent bacteria. After 8 weeks of immunosuppression with 265 
steroid, there were 90% of standard regimen treated mice and 95% of moxifloxacin 266 
replacement for ethambutol treated mice with CF-dependent cells which became CFU count 267 
positive again. This high disease relapse rate can only be feasibly explained by the reactivation 268 
of CF-dependent cells since the mice were CFU count-zero before immunosuppression. In 269 
addition to a lower relapse rate, mice treated with moxifloxacin replacement for isoniazid 270 
regimen contained similar MPN counts in their negative organs to the other two groups. This 271 
indicated that certain drug regimens such as moxifloxacin replacement of isoniazid may induce 272 
heterogeneously more diverse bacterial populations, therefore not all CF-responding bacteria 273 
regain their ability to form colonies on agar plates at the time we determined relapse, showing a 274 
lower disease relapse.  Further studies are warranted on the induction of heterogeneity of bacterial 275 
populations using different anti-TB drug regimens.  276 
Clinical trials and animal studies: different testbeds, same mechanism. None of the two 277 
moxifloxacin-replacement phase III clinical trials have demonstrated non-inferiority to 278 
standard regimens for treatment duration and disease relapses (3, 4); the underlying mechanism 279 
is unclear. An important finding of the REMoxTB trial is that there was a proportion of 280 
patients who showed sputum conversion quickly but continued to relapse after treatment with 281 
all three drug regimens (9). Our experiments suggest that the high relapse rates may have been 282 
due to CF-dependent bacilli (9)  which, till now, have remained undetectable using 283 
conventional culture methods, including those used in the clinical trials (3, 4, 9).  Persistent 284 
bacteria are established causes of prolonged chemotherapy and disease relapse (10). It has been 285 
repeatedly shown that in the Cornell mouse model, high relapse rate after treatment with the 286 
standard drug regimen was due to the presence of CF-dependent persistent bacteria (16, 17). 287 
Recently, we showed that drug regimens containing high doses of rifampicin (30 mg/kg or 288 
higher) could eliminate CF-dependent persistent bacilli, which led to shortened treatment 289 
duration from 14 weeks to just 6 weeks, without disease relapses (16, 18). The lesson learnt 290 
from the REMoxTB trial is that more rapid culture conversion in the short moxifloxacin 291 
containing regimens may not allow for shortened regimens due to the presence of persistent 292 
bacteria (9). A previous study also showed that early bactericidal activities of certain novel 293 
drug regimens were not necessarily predictive of any sterilizing effects (29). This may be 294 
attributed to the inability of the drug regimens to eliminate the persistent bacilli which were 295 
undetectable using the traditional microbiological methods. Therefore, in addition to the 296 
conventional microbiological methods, evaluation of anti-TB regimens by assessing their 297 
efficacies in eliminating RPF-dependent M. tuberculosis is important for providing a 298 
comprehensive profile of novel drug regimens before proceeding to human clinical trials. The 299 
combined data sets on CFU counts, broth growth and persister counts will strengthen any 300 
claims to be made on a regimen, which will ultimately increase the confidence of advancing it 301 
into humans. 302 
Clinical trials and animal studies: different testbeds and important considerations. The 303 
interpretation of the mouse results of moxifloxacin-replacement regimens compared with the 304 
results in clinical trials requires careful consideration.  In the previous animal studies for 305 
example  the burden of persistent bacteria had not been detected and assessed (5, 7) largely due 306 
to the undetectable feature of the persisters (16, 17). Importantly, there are clear differences in 307 
the pathophysiology of TB between humans and mice. Patients with active TB have persisters 308 
residing in a milieu of different pathogenic states, including necrotic/caseating lesions, central 309 
liquefactive lesions, open cavities, closed fibrotic granulomas (30, 31). Indeed, a patient over 310 
time may develop a combination of these lesions (10). Consequently, these heterogeneous 311 
persistent bacteria co-exist with fast growing bacteria at the time of the commencing antibiotic 312 
treatment (10). In contrast, mice do not form granuloma structures after M. tuberculosis 313 
infection (30) and persistent bacteria are generally low in absolute number (similar to the CFU 314 
counts) at the beginning of the treatment (16).  In addition, an important study has shown that 315 
moxifloxacin does not diffuse into caseating lesions, which may also lead to reduced sterilizing 316 
activities against persisters in human TB (32).  317 
Treatment of TB persisters is complex and future clinical trials require careful consideration of 318 
mechanistic in vivo studies, which can elucidate further insights into potential therapeutic 319 
targets. The study reported here represents an important step in the right direction by showing 320 
that RPF-dependent persisters may be a novel and important clinical therapeutic target.  321 
In conclusion, moxifloxacin substitution in contemporary drug regimens was ineffective 322 
against resuscitation promoting factor dependent persistent M. tuberculosis, despite having 323 
favorable therapeutic efficacy against actively multiplying bacteria in vivo.  324 
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Figure legend 457 
 458 
Figure 1.  Treatment profiles of M. tuberculosis H37Rv with regimens RHZE, RMZE and 459 
RHZM in the Cornell mouse model. A. Elimination of CFU counts in lungs. B. Elimination of 460 
CFU counts in spleens. The solid arrow indicates the treatment starting at 3 weeks of post 461 
infection. The empty arrow indicates starting steroid treatment after the termination of 14 week 462 















 Table 1. Mouse tuberculosis experimental design 
Treatment groupsa Total No. of miceb D0 D21 2W 4W 6W 8W 11W 14W 22Wc 
Control 8 4 4 
       RHZE 54 
  
4 4 4 8 8 8 22 
RHZM 54 
  
4 4 4 8 8 8 22 
RMZE 54 
  
4 4 4 8 8 8 22 
 
a
 Mice were intravenously infected at day 0. Treatment commenced at 21 days. Dosages for 
each drug were as follows: R 10 mg/kg, H 25 mg/kg, Z 150 mg/kg, E 100 mg/kg and M 100 
mg/kg. 
b 
 Total mice were infected and treated excluding natural death of the mice during the course 
of treatment  




 Table 2. Organ CFU counts before and after treatment with experimental regimens 
Time of infection 
and treatment 
Mean Log CFU per lung ± SD Mean Log CFU per spleen ± SD 
Control RHZE RHZM RMZE Control RHZE RHZM RMZE 
D0a 4.80 ± 0.14 
 
  
5.29 ± 0.03 
 
  D21b 7.54 ± 0.03 
 
  
6.99 ± 0.06 
 
  2Wc 
 
6.09 ± 0.03 5.92 ± 0.14 5.70 ± 0.12 
 
5.43 ± 0.08 5.54 ± 0.12 4.77 ± 0.10 
4W 
 
4.80 ± 0.07 4.52 ± 0.28 3.61 ± 0.16 
 
4.05 ± 0.02 4.49 ± 0.08 3.31 ± 0.21 
6W 
 
4.08 ± 0.11 4.00 ± 0.09 2.53 ± 0.29 
 
3.49 ± 0.16 3.81 ± 0.06 2.27 ± 0.20 
8W 
 
3.00 ± 0 3.25 ± 0.48 2.00 ± 0 
 
2.44 ± 0.22 3.24 ± 0.13 1.57 ± 0.20 
11Wd 
 
2.00 ± 0 2.00 ± 0 0 
 
1.19 ± 0.29 2.00 ± 0 0 
14Wd 
 
0 0 0 
 
0 0 0 
a. 2 hours post-infection. b. 21 days post-infection. c. week 2 post-treatment. d. CFU counts were derived from one third of tissue homogenate 
and limit detection was 3 CFU/organ. 
 
 
Table 3. Elimination constant rates of different treatment groups 
 
Elimination rate constant (wk-1)a 
Treatment group Lungsb Spleensc 
 
alpha %RSE alpha %RSE 
RHZE -0.46 3.20 -0.46 4.76 
RHZM -0.50 8.57 -0.46 6.54 
RMZE -0.65 10.96 -0.57 6.40 
 
a. Elimination rate constant equivalent to “knet_with_drug”   
b. P = 0.008 RMZE vs. RHZE, P = 0.065 RMZE vs. RHZM, P = 0.384 RHZE vs. RHZM 
c. P = 0.018 RMZE vs. RHZE, P = 0.011 RMZE vs. RHZM, P = 0.943 RHZE vs. RHZM 
P < 0.017 significant at 0.05 level after Bonferroni correction for 3 pairwise comparisons. 
 
 




MPN/lunga MPN/spleenb  
11 week 95% confidence limits  14 week 
95% confidence 
limits  11 week 
95% confidence 





2.50 ± 0.19 2.35 - 2.67 - 
 
2.56 ± 0.16 2.44 - 2.70 
RHZM - 
 
2.55 ± 0.14 2.44 - 2.67 - 
 
2.60 ± 0.09 2.52 - 2.69 
RMZE 2.96 ± 0.15 2.86 - 3.08 2.30 ± 0.23 2.15 - 2.50  3.01 ± 0.14 2.92 - 3.11 2.35 ± 0.16 2.27 - 2.45 
 
adetermined by MPN of the diluted lung homogenates (n=8)  with the culture filtrates. bdetermined by MPN of the diluted spleen homogenates 
(n=8)  with the culture filtrates.   
The CFU count zero organs showed no growth in Kirchner liquid medium following inoculation on Löwenstein-Jensen slopes. 
Broth counts were derived from one third of tissue homogenate and calculated to represent the MPN of entire organ. The limit of detection was 
30 MPN/organ.  
-, Colony count positive and MPN counts not performed organs. The limit of detection was 3 CFU/organ. 
 
Table 5. Relapse rates of mice after treatment with different drug regimens 
Positive culture from RHZE RHZM RMZE 
Spleen only 3 5 4 
Lung only 0 2 5 
Both organs 16 13 4 
Neither organs 2 1 9 
Total mice 21 21 22 
Relapse rate pn/N (%)a 19/21 (90)  20/21 (95)  13/22 (59)  
MPN in CFU count negative organs 3.30 ± 0.13 3.51 ± 0.11 3.05 ± 0.18 
 
a, Relapse rates include all lungs or spleens or both organs positive for bacilli. N, total 
number of mice.  pn, number of mice with CFU count positive organs. 
P = 0.03 RMZE vs. RHZE, P = 0.009 RMZE vs. RHZM, P = 1 RHZE vs. RHZM 


















































Weeks of treatment 
RHZE Obs
RHZE Fit
RHZM Obs
RHZM Fit
RMZE Obs
RMZE Fit
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